Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-04-2020 | Neutropenia | Original Article

“Hairy Cell Leukemia (HCL): ‘Real World’ Outcome”

Authors: Archit Joshi, Manikandan Dhanushkodi, Prasanth Ganesan, Venkatraman Radhakrishnan, Krishnarathinam Kannan, Nikita Mehra, Jayachandran Perumal Kalaiyarasi, S. Krupashankar, Shirley Sundersingh, T. S. Ganesan, T. G. Sagar

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Abstract

HCL is an uncommon B cell lympho-proliferative disorder with high remission rates. There is paucity of data on the long-term outcome of HCL from India. We retrospectively collected data from individual case records of patients with HCL who were treated in Cancer Institute, Chennai from January 2001 until January 2018. Sixteen patients were diagnosed with HCL and were treated with cladribine (81%), interferon (13%) and one patient received only best supportive care (6%). All the treated patients achieved complete response. More than half of the patients developed febrile neutropenia but there were no treatment related mortality. The 5-year DFS was 77% and 5-year OS was 80%. Relapse of disease was seen in 27%. HCL is a curable malignancy with high remission rates and survival comparable to patient treated in west.

Jain P, Pemmaraju N, Ravandi F (2014) Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol 15:187–209CrossRef

Polliack A (2002) Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 6(4):366–388CrossRef

Bouroncle BA (1979) Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 53:412–436CrossRef

Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZS et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol

Grever MR, Abdel-Wahab O, Andritsos LA et al (2017) Consensus guidelines for the diagnosis and management of patients with classical hairy cell leukemia. Blood 129:553–560CrossRef

Somasundaram V, Purohit A, Aggarwal M, Manivannan P, Mishra P, Seth T et al (2014) Hairy cell leukemia: a decade long experience of North Indian Hematology Center. Indian J Med Paediatr Oncol 35:271–275CrossRef

Abraham LJ, Saldanha SC, Kuntegowdanahalli LC, Bharatnur S, Dasappa L, Babu G, Babu MS, Kiran PR (2016) Hairy cell leukemia—clinical profile and treatment outcome from a Tertiary Regional Cancer Institute in South India. Clin Cancer Investig J 5:141–145CrossRef

Naing PT, Acharya U (2018) Cancer, leukemia, hairy cell. In: StatPearls. StatPearls Publishing, Treasure Island (FL). http://www.ncbi.nlm.nih.gov/books/NBK499845/. Accessed 9 Sept 2018

Favre R, Manzoni D, Traverse-Glehen A, Verney A, Jallades L, Callet-Bauchu E, Sujobert P, Salles G, Baseggio L (2018) Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Int J Lab Hematol 40(4):e59–e62. https://doi.org/10.1111/ijlh.12824 CrossRefPubMed

10.

Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115(10):1893–1896. https://doi.org/10.1182/blood-2009-10-251645 CrossRefPubMed

11.

Kreitman RJ et al (2018) Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. https://www.ncbi.nlm.nih.gov/pubmed/29487070. Accessed 19 Nov 2018

12.

Lad DP, Malhotra P, Khadwal A et al (2014) Outcomes of splenectomy versus cladribine for hairy cell leukemia in resource limited settings. Leukemia Lymphoma 55(6):1428–1430. https://doi.org/10.3109/10428194.2013.839786 CrossRefPubMed

13.

Golomb HM (2008) Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol 26(16):2607–2609CrossRef

14.

Dinmohamed AG, Posthuma EFM, Visser O, Kater AP, Raymakers RAP, Doorduijn JK (2018) Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. Blood 131(12):1380–1383. https://doi.org/10.1182/blood-2017-12-820381 CrossRefPubMed

15.

Andrasiak I, Rybka J, Wrobel T (2018) Response to the therapy in hairy cell leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leukemia 18:392–399CrossRef

16.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE et al (2018) Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 32(8):1768–1777. https://doi.org/10.1038/s41375-018-0210-1 CrossRefPubMedPubMedCentral

17.

Andritsos LA, Grieselhuber NR, Anghelina M, Rogers KA, Roychowdhury S, Reeser JW, Timmers CD et al (2018) Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia Lymphoma 59(4):1008–1011. https://doi.org/10.1080/10428194.2017.1365853 CrossRefPubMed

18.

Kreitman RJ, Arons E (2018) Update on hairy cell leukemia. Clin Adv Hematol Oncol H&O 16(3):205–215

19.

Maitre E, Bertrand P, Maingonnat C, Viailly P-J, Wiber M, Naguib D, Salaün V et al (2018) New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. Oncotarget 9(48):28866–28876. https://doi.org/10.18632/oncotarget.25601 CrossRefPubMedPubMedCentral

20.

21.

Galani KS, Subramanian PG, Gadage VS, Rahman K, Ashok Kumar MS, Shinde S et al (2012) Clinico-pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 55:61–65CrossRef

22.

Medhi K et al (2006) Hairy cell leukemia: experience at a tertiary cancer centre in Northern India. Indian J Med Paediatric Oncol 27(1):8–14

23.

Gupta AK, Sachdeva MUS, Ahluwalia J et al (2015) Haematological profile of 21 patients with hairy cell leukaemia in a tertiary care centre of north India. Indian J Med Res 142(4):426–429CrossRef

24.

Chatterjee T, Panigrahi I, Mahapatra M, Pati HP, Kumar R, Naithani R et al (2008) Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian-Indians. Indian J Cancer 45:41–44CrossRef

Title: “Hairy Cell Leukemia (HCL): ‘Real World’ Outcome”
Authors: Archit Joshi
Manikandan Dhanushkodi
Prasanth Ganesan
Venkatraman Radhakrishnan
Krishnarathinam Kannan
Nikita Mehra
Jayachandran Perumal Kalaiyarasi
S. Krupashankar
Shirley Sundersingh
T. S. Ganesan
T. G. Sagar
Publication date: 01-04-2020
Publisher: Springer India
Keywords: Neutropenia
Cladribine
Leukemia
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-019-01199-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Blocking Phenomenon Occurs in a Neonate with a Positive Direct Antiglobulin Test Due to Maternal Anti-D, Anti-C Antibodies: Resolved by Chloroquine Diphosphate Treatment

Combined Immature Platelet Fraction and Schistocyte Count to Differentiate Pregnancy-Associated Thrombotic Thrombocytopenic Purpura from Severe Preeclampsia/Haemolysis, Elevated Liver Enzymes, and Low Platelet Syndrome (SPE/HELLP)

CRAB Positive Acute Lymphoblastic Leukemia, Masquerader of Multiple Myeloma

Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases

Inadequate Pre-conception Counseling is a Major Challenge for Antenatal Management of β-Thalassemia: Experience from a Referral Centre in India

Inherited Bleeding Disorders in North Indian Children: 14 years’ Experience from a Tertiary Care Center

Keynote webinar | Spotlight on antibody–drug conjugates in cancer